Replimune Group, Inc.
REPLNASDAQHealthcare● Active
$8.76
$-0.71(-7.50%)
Market Cap$723336142
P/E Ratio—
52W High$13.24
52W Low$1.5
Replimune Group, Inc. (REPL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
REPL · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 3, 2026EPS Actual
-$0.77
Est. -$0.77 · -0.2%
Revenue
—
Est. $0.00B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 3, 2026
After Market Close
REPL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.63 | — | — | — | $0.01B | — |
| ◌ Q2 FY2026 | Jun 11, 2026 | -$0.73 | — | — | — | $0.01B | — |
| — Q1 FY2026 | Feb 3, 2026 | -$0.77 | -$0.77 | -0.2% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.87 | -$0.90 | -3.5% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.83 | -$0.95 | -14.5% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 22, 2025 | -$0.75 | -$0.82 | -9.3% | $0.00B | — | — |
| ▼ Q1 FY2025 | Feb 12, 2025 | -$0.70 | -$0.79 | -12.9% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.75 | -$0.68 | +9.3% | — | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 11, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 3, 2026
EPS Actual
-$0.77
EPS Est.
-$0.77
EPS Surpr.
-0.2%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.90
EPS Est.
-$0.87
EPS Surpr.
-3.5%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.95
EPS Est.
-$0.83
EPS Surpr.
-14.5%
Revenue
—
Q2 FY2025
May 22, 2025Miss
EPS Actual
-$0.82
EPS Est.
-$0.75
EPS Surpr.
-9.3%
Revenue
$0.00B
Q1 FY2025
Feb 12, 2025Miss
EPS Actual
-$0.79
EPS Est.
-$0.70
EPS Surpr.
-12.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.68
EPS Est.
-$0.75
EPS Surpr.
+9.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.14 | $0.14 | $0.14 | 2 |
| Q4 FY2029 | $0.15 | $0.15 | $0.15 | 2 |
| Q3 FY2029 | $0.13 | $0.13 | $0.13 | 1 |
| Q2 FY2029 | $0.09 | $0.09 | $0.09 | 1 |
| Q1 FY2029 | $0.06 | $0.06 | $0.06 | 2 |
| Q4 FY2028 | $0.05 | $0.05 | $0.05 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2029 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2029 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Feb 3, 2026 | -0.2% | $6.98 | $7.38 | +5.73% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -3.5% | $8.58 | $8.50 | -0.93% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -14.5% | $5.50 | $5.48 | -0.36% |
| ▼ Q2 FY2025 | May 22, 2025 | -9.3% | $8.46 | $8.76 | +3.55% |
| ▼ Q1 FY2025 | Feb 12, 2025 | -12.9% | $12.85 | $13.79 | +7.32% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +9.3% | $12.50 | $12.19 | -2.48% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +11.4% | $9.20 | $9.45 | +2.72% |
| ▲ Q2 FY2024 | May 16, 2024 | +4.7% | $6.81 | $6.72 | -1.32% |
Q1 FY2026+5.73%
Report Date
Feb 3, 2026
EPS Beat/Miss
-0.2%
Price Before
$6.98
Price After
$7.38
Q4 FY2025-0.93%
Report Date
Nov 6, 2025
EPS Beat/Miss
-3.5%
Price Before
$8.58
Price After
$8.50
Q3 FY2025-0.36%
Report Date
Aug 7, 2025
EPS Beat/Miss
-14.5%
Price Before
$5.50
Price After
$5.48
Q2 FY2025+3.55%
Report Date
May 22, 2025
EPS Beat/Miss
-9.3%
Price Before
$8.46
Price After
$8.76
Q1 FY2025+7.32%
Report Date
Feb 12, 2025
EPS Beat/Miss
-12.9%
Price Before
$12.85
Price After
$13.79
Q4 FY2024-2.48%
Report Date
Nov 12, 2024
EPS Beat/Miss
+9.3%
Price Before
$12.50
Price After
$12.19
Q3 FY2024+2.72%
Report Date
Aug 8, 2024
EPS Beat/Miss
+11.4%
Price Before
$9.20
Price After
$9.45
Q2 FY2024-1.32%
Report Date
May 16, 2024
EPS Beat/Miss
+4.7%
Price Before
$6.81
Price After
$6.72
Avg Beat Reaction+1.16%
Avg Miss Reaction+2.40%
Beat Rate4 / 8 quarters
Largest Move+7.32% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: REPL ends December
Replimune Group, Inc. (REPL) most recently reported earnings on February 3, 2026 for Q1 FY2026, posting EPS of $-0.77 (in line with the analyst consensus of $-0.77). The next REPL earnings date is expected around September 1, 2026.
Each quarter, investors track REPL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. REPL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
REPL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
REPL earnings · 4 questionsReplimune Group, Inc.'s next earnings report is expected around September 1, 2026. REPL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; REPL historically reports after market close (AMC).
REPL earnings datewhen is REPL earningsREPL next earnings datewhen does REPL report earningsREPL earnings calendar
▸ Source: FMP · Replimune Group, Inc. SEC filings · US GAAP · Replimune Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026